Online inquiry

IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10413MR)

This product GTTS-WQ10413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10413MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10408MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ9754MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ10862MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ7119MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ10893MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ7539MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ14461MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ8274MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW